Selected Grants
LpxH Inhibitors as Novel Therapeutics Against Multidrug-resistant Enterobacterales
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2030Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient Mortality
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2027OPTIMIZE
ResearchPrincipal Investigator · Awarded by DCRI-Duke-Site · 2023 - 2026Identification of novel pathogen-specific drug targets in gram-negative bacteria (JCVI CDC U54 - Medium Collaborative)
ResearchPrincipal Investigator · Awarded by J. Craig Venter Institute · 2021 - 2025Optimizing the Outcomes of Adults with Gram-Negative Bloodstream Infections
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2023 - 2025Duke CTSA (KL2)
ResearchScholar · Awarded by National Institutes of Health · 2018 - 2024IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens
ResearchCo Investigator · Awarded by Valanbio Therapeutics, Inc. · 2020 - 2022Systems Immunobiology of Antibiotic-Persistent MRSA Infections
ResearchInvestigator · Awarded by The Lundquist Institute · 2016 - 2021Prospective epidemiological study to estimate the O-serotype distribution of extraintestinal pathogenic Escherichia coli (ExPEC) isolated from hospitalized patients aged 60 years or older with invasive ExPEC disease (IED) and to evaluate the clinical
ResearchPrincipal Investigator · Awarded by University Medical Center Utrecht · 2019 - 2021Janssen ExPEC Study
ResearchPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2019 - 2020VTEU 13-0053 Task Area B: Phase I, single dose, open-label, parallel group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, normal, healthy subjects.
ResearchFellow · Awarded by National Institutes of Health · 2014 - 2015External Relationships
- ESCMID
- Resonantia Diagnostics, Inc.
- Sanofi
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.